Evidence map›Paper›PMID 41197733›Full record

ArticleThe Journal of biological chemistry2025

Biochemical characterization of the full-length isoform of soluble adenylyl cyclase.

Jacob Ferreira, Hayden Belliveau, Lonny R Levin, Jochen Buck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jacob FerreiraDepartment of Pharmacology, Weill Cornell Medicine, New York, New York, USA.
Hayden BelliveauDepartment of Pharmacology, Weill Cornell Medicine, New York, New York, USA.
Lonny R LevinDepartment of Pharmacology, Weill Cornell Medicine, New York, New York, USA. Electronic address: llevin@med.cornell.edu.
Jochen BuckDepartment of Pharmacology, Weill Cornell Medicine, New York, New York, USA.

Funding

Target EngagementP50HD113015 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVIN, LONNY R · 2023 to 2025
$6.0M
Optimization of lead candidates for an on-demand male contraceptiveR01HD111549 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOCHEN BUCK, LONNY R LEVIN · 2023 to 2026
$2.7M
Discovery and Characterization of an Endogenous Inhibitor of Soluble Adenylyl CyclaseF31HD105363 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI FERREIRA, JACOB · 2021 to 2023
$140k
NICHD NIH HHS F31 HD105363NICHD NIH HHS P50 HD113015NICHD NIH HHS R01 HD111549
6 · The paper itself

Abstract

cAMP is a ubiquitous second messenger produced from ATP and involved in many cellular processes. In humans, cAMP is produced from two types of adenylyl cyclases: G protein-regulated transmembrane adenylyl cyclases (ADCY1-9) and bicarbonate- (HCO

Indexed as

Adenylyl CyclasesAnimalsGene Knock-In TechniquesHSP70 Heat-Shock ProteinsHumansIsoenzymesMaleMiceMice, Mutant StrainsTestisADCY10 protein, humanAdenylyl CyclasesHSP70 Heat-Shock ProteinsIsoenzymesACDY10bicarbonatecalciumcyclic adenosine monophosphate (cAMP)isoformssoluble adenylyl cyclase (sAC)

Identifiers

PMID41197733
PMCPMC12802110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.